CA-JUNIPER-NETWORKS
Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that it has been selected by Deutsche Telekom (DT) as the first network technology partner for Magenta Business Networks SD-X. By leveraging the Juniper AI-driven Enterprise solution, DT’s innovative new universal managed services platform will power exceptional user experiences with simplified zero touch deployments, proactive self-driving automation, connected security and unique client-to-cloud insight.
SD-X is a cloud-based, virtualized and automated platform that will provide a rapid, simplified and cost-effective transition from MPLS to software-defined network services for thousands of European enterprises, including small-to-midsize organizations that might otherwise find the cost and complexity of owned infrastructure to be prohibitive. Juniper is providing DT with advanced technologies to create a secure, software-driven network fabric that uses AI to provide actionable insights on real-time performance coupled with automated mitigation. This approach enables SD-X to deliver optimal user, device and application experiences to its customers as they navigate digital transformation in support of agile, differentiated business capabilities. The managed services offered provide secure networking for campus and branch environments, enabling rich new service functionality and enhanced performance.
News Highlights
- Magenta Business Networks SD-X will leverage Juniper’s full AI-driven Enterprise portfolio, starting with secure SD-WAN and expanding to wired and wireless access.
- The Juniper solution provides client-to-cloud service levels with AI-driven intelligence to optimize and maintain the best user experiences. With AI-driven insight, problems are proactively discovered and addressed via recommended actions and/or self-driving network operations. This minimizes downtime while maximizing end user experiences on the SD-X network.
- Zero touch provisioning with automated workflows enable the SD-X solution services to be pre-configured and easily deployed remotely, saving time and money while minimizing installation errors. The time for new network services to be up-and-running is reduced from weeks or months to just a few days.
- Customers can easily change network policies and security settings remotely at any time using a cloud-hosted SD-X portal, with no manual intervention or site visits needed. Simultaneous updates can be made across a customer’s entire network, so consistent policies are applied between sites.
- By leveraging a microservices cloud, DT can easily update services across the entire Juniper portfolio with little to no downtime.
AI-driven Automation, Insight and Assurance Powers User Experience
The network is the digital lifeblood of today’s enterprise, requiring anywhere, anytime access between users and data. But increased levels of traffic, diversity in devices and distributed location of users can make it extremely challenging to deliver great experiences from client-to cloud. By deploying “smart” AI-driven networking technology from Juniper that can understand user behavior in real-time and automatically optimize the network to lower costs and maximize experiences, SD-X is able to deliver a differentiated and compelling managed service to its subscribers.
Supporting Quotes
“With the relentless pace and demands of modern businesses, our customers need managed services that optimize user experiences while minimizing operational costs. We have built SD-X as a gateway to accessible, progressive enterprise networking without the need for advanced in-house capabilities and technical resources. DT’s vision is made possible thanks to Juniper’s innovation with AI, automation and the cloud, which creates an agile network for our customers that is highly differentiated in the industry.”
- Sherif Rezkalla, VP Portfolio, Head of Business Networks, Deutsche Telekom
“DT has fully embraced the powerful value of intelligent networks with SD-X. This highly-scalable business model is more cost-effective than traditional approaches, while providing the agility and ease of use customers demand. In turn, these customers can use SD-X as the foundation for an experience-driven digital business for their own customers and employees. We look forward to working with DT to roll out more managed services across SD-X to deliver a game-changing networking experience.”
- Manoj Leelanivas, Chief Operating Officer, Juniper Networks
Additional Resources
Case Study: Deutsche Telekom transforms network service delivery
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
category-enterprise
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221212005118/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom